Copyright
©The Author(s) 2021.
World J Diabetes. Mar 15, 2021; 12(3): 292-305
Published online Mar 15, 2021. doi: 10.4239/wjd.v12.i3.292
Published online Mar 15, 2021. doi: 10.4239/wjd.v12.i3.292
Variable | Baseline | 2 mo | 6 mo | 12 mo | ||||||||||||
CBT | Control | χ2/t value | P value | CBT | Control | χ2/t value | P value | CBT | Control | χ2/t value | P value | CBT | Control | χ2/t value | P value | |
Participant number | 568 | 574 | --- | --- | 550 | 559 | 541 | 549 | --- | --- | 506 | 527 | --- | --- | ||
Gender (female) | ||||||||||||||||
Female | 370 | 383 | 0.32 | 0.57 | 362 | 376 | 0.26 | 0.61 | 356 | 370 | 0.31 | 0.58 | 335 | 367 | 1.40 | 0.24 |
Age (mean + SD) | 61.58 ± 9.17 | 61.83 ± 8.64 | -0.46 | 0.65 | 61.75 ± 9.12 | 62.10 ± 8.86 | -0.64 | 0.52 | 62.48 ± 9.14 | 62.75 ± 8.71 | -0.50 | 0.62 | 62.87 ± 9.25 | 62.74 ± 8.87 | 0.23 | 0.82 |
Educational level | ||||||||||||||||
High school and above | 53 | 56 | 0.42 | 0.81 | 51 | 56 | 0.38 | 0.83 | 47 | 56 | 1.09 | 0.58 | 41 | 50 | 1.00 | 0.61 |
Junior high school | 240 | 251 | 234 | 243 | 231 | 240 | 208 | 223 | ||||||||
High school and above | 275 | 267 | 265 | 260 | 263 | 253 | 257 | 254 | ||||||||
Hypertension | 287 | 287 | 0.03 | 0.86 | 276 | 278 | 0.02 | 0.88 | 270 | 272 | 0.01 | 0.91 | 252 | 262 | 0.00 | 0.98 |
Comorbidities | 109 | 118 | 0.34 | 0.56 | 109 | 114 | 0.06 | 0.81 | 107 | 110 | 0.01 | 0.92 | 91 | 110 | 1.37 | 0.24 |
BMI | 24.77± 4.15 | 25.20± 4.94 | -1.60 | 0.11 | 24.99 ± 4.48 | 25.00 ± 4.94 | -0.06 | 0.96 | 24.71 ± 4.09 | 25.22 ± 5.01 | -1.84 | 0.07 | 24.76 ± 4.00 | 25.28 ± 5.02 | -1.84 | 0.07 |
Drinking | 55 | 66 | 0.99 | 0.32 | 55 | 65 | 0.76 | 0.38 | 54 | 64 | 0.79 | 0.37 | 46 | 49 | 0.01 | 0.91 |
Smoking | 80 | 92 | 0.84 | 0.36 | 79 | 88 | 0.41 | 0.52 | 76 | 86 | 0.56 | 0.45 | 64 | 69 | 0.05 | 0.83 |
Course of the disease (yr) | 5.07 ± 5.25 | 5.21 ± 4.91 | 0.56 | 0.64 | 5.20 ± 5.06 | 5.41 ± 5.36 | -0.66 | 0.51 | 5.53 ± 5.21 | 5.66 ± 4.76 | -0.43 | 0.67 | 6.03 ± 5.28 | 6.20 ± 4.68 | -0.52 | 0.60 |
Medication | ||||||||||||||||
Oral hypoglycemic agents | 491 | 483 | 1.56 | 0.46 | 476 | 470 | 1.76 | 0.42 | 472 | 465 | 1.72 | 0.42 | 448 | 444 | 5.96 | 0.05 |
Insulin | 45 | 49 | 42 | 46 | 39 | 44 | 37 | 43 | ||||||||
Oral hypoglycemic agents plus insulin | 32 | 42 | 32 | 43 | 30 | 40 | 21 | 40 | ||||||||
GAD-7 score | 7.56 ± 5.20 | 7.58 ± 5.25 | -0.04 | 0.97 | 7.47 ± 5.23 | 7.22 ± 5.48 | 0.76 | 0.45 | 7.53 ± 5.65 | 7.14 ± 5.93 | 1.10 | 0.27 | 7.14 ± 5.68 | 6.34 ± 5.56 | 2.27 | 0.02 |
PHQ-9 score | 7.13 ± 5.53 | 6.94 ± 5.47 | 0.59 | 0.55 | 7.23 ± 5.36 | 7.00 ± 5.02 | 0.73 | 0.46 | 7.21 ± 5.48 | 6.74 ± 5.21 | 1.44 | 0.15 | 7.20 ± 5.45 | 6.10 ± 4.97 | 3.39 | 0.00 |
- Citation: Zhang HZ, Zhang P, Chang GQ, Xiang QY, Cao H, Zhou JY, Dong ZM, Qiao C, Xu CR, Qin Y, Lou PA. Effectiveness of cognitive behavior therapy for sleep disturbance and glycemic control in persons with type 2 diabetes mellitus: A community-based randomized controlled trial in China. World J Diabetes 2021; 12(3): 292-305
- URL: https://www.wjgnet.com/1948-9358/full/v12/i3/292.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i3.292